Platelet Rich Plasma (PRP) One-Shot Injection For Supraspinatus Tendinosis

N/ACompletedNCT04851951

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari48 enrolled

Overview

It was conducted a prospective study with a series of 50 patients treated with PRP one-shot injection in patient affected by Supraspinatus Tendinosis. One independent observer performed clinical and functional evaluations at T0 (recruitment), T1 (one month after the injection), T2 (three months after the last injection) and T3 (six months after the last injection). Constant Score, The Disabilites of the Arm,Shoulder and Hand Score (DASH) And Visual Analogue Scale (VAS) were administered at each evaluation.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Supraspinatus Tendinitis

Interventions

one-shot PRP injectionPROCEDURE

A single injection of PRP (7% concentrate) ml 4 was made in the Supraspinatus tendon and in the Subacromial space under ultrasound guidance.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years old; * Supraspinatus tendinosis detected by MRI. Exclusion Criteria: * Supraspinatus rupture; * Previous shoulder surgery; * Rotator cuff tears secondary to fracture; * Hemoglobin \<7 g/dL or Platelets \< 30,000 microL; * Active infection; * Pregnant patients; * Patients with hematologic and oncologic diseases.

Locations (1)

AOUC Policlinico di Bari - UOC Ortopedia e Traumatologia

Bari, Italy

Outcomes

Primary Outcomes

Change in Visual Analogic Scale

The shoulder pain was quantified using the Visual Analogic Scale ranging from 0 (no pain) to 10 (worst imaginable pain).

Time frame: Day 0; Month 1; Month 3; Month 6 (after the injection)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.